![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1671854
ÀÇ·á µ¿Çà ¼ºñ½º ½ÃÀå : ¼ºñ½º À¯Çüº°, ȯÀÚ À¯Çüº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°Medical Accompaniment Service Market, By Service Type, By Patient Type, By End User, By Geography |
¼¼°èÀÇ ÀÇ·á µ¿Çà ¼ºñ½º ½ÃÀåÀº 2025³â¿¡´Â 4,860¸¸ ´Þ·¯·Î ÃßÁ¤µÇ¸ç 2032³â¿¡´Â 8,120¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2025-2032³â ¿¬Æò±Õ 7.6%ÀÇ ¿¬Æò±Õ ¼ºÀå·ü(CAGR)·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
º¸°í ´ë»ó ¹üÀ§ | º¸°í¼ »ó¼¼ ³»¿ë | ||
---|---|---|---|
±âÁØ¿¬µµ | 2024³â | 2025³â ½ÃÀå ±Ô¸ð | 4,860¸¸ ´Þ·¯ |
½ÇÀû µ¥ÀÌÅÍ | 2020-2024³â | ¿¹Ãø ±â°£ | 2025-2032³â |
¿¹Ãø ±â°£ : 2025-2032³â CAGR: | 7.60% | 2032³â °¡Ä¡ ¿¹Ãø | 8,120¸¸ ´Þ·¯ |
¼¼°è ÀÇ·á µ¿Çà ¼ºñ½º ½ÃÀåÀº ¾çÁúÀÇ ÀÇ·á ¼ºñ½º¿Í Àå±âÀûÀÎ ÀÇ·á ¼ºñ½º¸¦ ÇÊ¿ä·Î Çϴ ȯÀÚ Áö¿ø¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó ÃÖ±Ù ¼ö³â°£ °ý¸ñÇÒ ¸¸ÇÑ ¼ºÀåÀ» ÀÌ·ç¾ú½À´Ï´Ù. ÀÇ·á µ¿Çà ¼ºñ½º´Â ³»ºñ°ÔÀ̼Ç, ¹ø¿ª, À̵¿, µ¿Çà ¹× ±âŸ ºñÀÓ»ó ¼ºñ½º·Î ȯÀÚ¸¦ Áö¿øÇÏ¿© ȯÀÚ°¡ ÃÖÀûÀÇ Ä¡·á¸¦ ¹ÞÀ» ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù. »ýȰ½À°üº´°ú ³ëÈ °ü·Ã Áúº´ÀÌ Áõ°¡ÇÔ¿¡ µû¶ó Ä¡·á ¹× ȸº¹ °úÁ¤ÀÇ ¹°·ù¸¦ °£¼ÒÈÇϰí Á¤½ÅÀû ÁöÁö¸¦ º¸ÀåÇϱâ À§ÇØ ÀÌ·¯ÇÑ º¸Á¶ ¼ºñ½º¸¦ ¼±ÅÃÇϴ ȯÀÚ°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.
ÀÇ·á µ¿Çà ¼ºñ½º ½ÃÀåÀÇ ÁÖ¿ä ¼ºÀå ÃËÁø¿äÀÎÀ¸·Î´Â ¸¸¼ºÁúȯ¿¡ Ãë¾àÇÑ ³ëÀÎ Àα¸ Áõ°¡, ´Ü¼øÇÑ ÀÓ»ó Ä¡·áº¸´Ù ÀüÀÎÀû °Ç°¿¡ ´ëÇÑ °ü½É Áõ°¡, °£º´ÀÎ ºÎÁ· µîÀ» ²ÅÀ» ¼ö ÀÖ½À´Ï´Ù. ±×·¯³ª µ¥ÀÌÅÍ ÇÁ¶óÀ̹ö½Ã¿¡ ´ëÇÑ ¿ì·Á¿Í ¹ý±ÔÁؼö ¹®Á¦°¡ °úÁ¦·Î ´ëµÎµÇ°í ÀÖ½À´Ï´Ù. ±àÁ¤ÀûÀÎ Ãø¸é¿¡¼´Â ÀÇ·á°ü±¤ÀÇ ±Þ¼ÓÇÑ È®´ë¿Í ¸ÂÃãÇü ÀÇ·á Çõ¸íÀÌ À¯¸®ÇÑ ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ Áö¹æ¿¡¼ÀÇ ¼ºñ½º Á¶Á¤ ¹× Á¢±Ù¼º Çâ»óÀ» À§ÇÑ Ã·´Ü µðÁöÅÐ ¼Ö·ç¼ÇÀÇ ÅëÇÕÀº ÇâÈÄ ½ÃÀå È®´ë¸¦ ´õ¿í °¡¼ÓÈÇÒ ¼ö ÀÖ½À´Ï´Ù.
¼¼°èÀÇ ÀÇ·á µ¿Çà ¼ºñ½º ½ÃÀåÀ» »ó¼¼ÇÏ°Ô ºÐ¼®ÇßÀ¸¸ç, 2024³âÀ» ±âÁØ ¿¬µµ·Î ÇÏ¿© ¿¹Ãø ±â°£(2025-2032³â) ½ÃÀå ±Ô¸ð¿Í ¿¬Æò±Õ ¼ºÀå·ü(CAGR)À» Á¶»çÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
¶ÇÇÑ ´Ù¾çÇÑ ºÎ¹®¿¡ °ÉÄ£ ÀáÀçÀû ¸ÅÃâ ±âȸ¸¦ ¹àÈ÷°í, ÀÌ ½ÃÀåÀÇ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È ¸ÅÆ®¸¯½º¸¦ ¼³¸íÇÕ´Ï´Ù.
¶ÇÇÑ ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½Å±Ô ¼ºñ½º ¹ßÇ¥ ¹× ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä ±â¾÷ÀÇ °æÀï Àü·« µî¿¡ ´ëÇÑ ÁÖ¿ä ÀλçÀÌÆ®µµ Á¦°øÇÕ´Ï´Ù.
ÀÌ º¸°í¼´Â ±â¾÷ ÇÏÀ̶óÀÌÆ®, ¼ºñ½º Æ÷Æ®Æú¸®¿À, ÁÖ¿ä ÇÏÀ̶óÀÌÆ®, À繫 ¼º°ú, Àü·« µîÀÇ ¸Å°³ º¯¼ö¸¦ ±â¹ÝÀ¸·Î ¼¼°è ÀÇ·á µ¿Çà ¼ºñ½º ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷À» ÇÁ·ÎÆÄÀϸµÇÕ´Ï´Ù.
ÁÖ¿ä ±â¾÷¿¡´Â GlaxoSmithKline plc, Sanaria Inc., Nobelpharma Co., Sumaya Biotech, GenVec, Merck & Co., Inc., Pfizer Inc., Johnson & Johnson, Bharat Biotech, Serum Institute of India, Takeda Pharmaceutical Company, Novavax, Inc., Inovio Pharmaceuticals, Vaxart, Inc., BioNTech SE µîÀÌ ÀÖ½À´Ï´Ù.
ÀÌ º¸°í¼ÀÇ ÀλçÀÌÆ®¸¦ ÅëÇØ ¸¶ÄÉÆÃ ´ã´çÀÚ¿Í ±â¾÷ °æ¿µÁøÀº ÇâÈÄ ¼ºñ½º Ãâ½Ã, È®Àå, Á¦ÈÞ, ¸¶ÄÉÆÃ Àü·«¿¡ ´ëÇÑ Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù.
¼¼°è ÀÇ·á µ¿Çà ¼ºñ½º ½ÃÀå º¸°í¼´Â ¼ºñ½º ÇÁ·Î¹ÙÀÌ´õ, ÀÇ·á ±â°ü, ÁöºÒÀÚ, ±ÔÁ¦ ´ç±¹, ½Å±Ô ½ÃÀå ÁøÃâ±â¾÷ µî ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¸¦ ´ë»óÀ¸·Î ÇÕ´Ï´Ù.
ÀÌÇØ°ü°èÀÚµéÀº º» Á¶»ç¿¡¼ Á¦°øÇÏ´Â ´Ù¾çÇÑ ½ÃÀå µ¥ÀÌÅÍ ºÐ¼®À» ÅëÇØ ÀÇ»ç°áÁ¤À» ½±°Ô ÇÒ ¼ö ÀÖ½À´Ï´Ù.
Global Medical Accompaniment Service Market is estimated to be valued at US$ 48.6 Mn in 2025 and is expected to reach US$ 81.2 Mn by 2032, growing at a compound annual growth rate (CAGR) of 7.6% from 2025 to 2032.
Report Coverage | Report Details | ||
---|---|---|---|
Base Year: | 2024 | Market Size in 2025: | US$ 48.6 Mn |
Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
Forecast Period 2025 to 2032 CAGR: | 7.60% | 2032 Value Projection: | US$ 81.2 Mn |
The global medical accompaniment service market has been witnessing significant growth in the recent past owing to the rising demand for quality healthcare services and support for patients requiring long-term medical care. Medical accompaniment services help patients in navigation, translation, transportation, companionship, and other non-clinical services allowing them to receive optimal care. As lifestyle diseases and age-related illnesses are on the rise, more patients are opting for these supplementary services to simplify logistics and ensure emotional support during their treatment or recovery process.
The primary growth drivers for the medical accompaniment service market include growing geriatric population base susceptible to chronic diseases, increasing preference for holistic wellness over mere clinical treatment, and shortage of caretakers. However, data privacy concerns and legal compliance issues pose challenges. On the positive side, rapid medical tourism expansion and personalized healthcare revolution are opening lucrative opportunities. Moreover, integration of advanced digital solutions for service coordination and improved access in rural regions can further accelerate the market expansion going forward.
This report provides in-depth analysis of the global medical accompaniment service market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new service launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global medical accompaniment service market based on the following parameters - company highlights, service portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include GlaxoSmithKline plc, Sanaria Inc., Nobelpharma Co., Sumaya Biotech, GenVec, Merck & Co., Inc., Pfizer Inc., Johnson & Johnson, Bharat Biotech, Serum Institute of India, Takeda Pharmaceutical Company, Novavax, Inc., Inovio Pharmaceuticals, Vaxart, Inc., and BioNTech SE
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future service launches, expansions, collaborations and marketing tactics
The global medical accompaniment service market report caters to various stakeholders in this industry including service providers, healthcare organizations, payers, regulators and new entrants
Stakeholders would have ease in decision-making through various market data analyses provided in the study